| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
REVIEW ARTICLE |
Cochrane Schizophrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds UK
Institute of Mental Health, Chengdu, China
Chinese Cochrane Centre, West China Hospital of Sichuan University, Chengdu, China
Cochrane Schizophrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds, UK
Institute of Mental Health, West China Hospital of Sichuan University, Chengdu, China
Cochrane Schizophrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds, UK
Correspondence: John Rathbone, Rathbone, Cochrane Schizop Schizophrenia hrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds,15 Hyde Terrace, Leeds LS2 9LT, UK. Tel: +44 (0)113 343 1897; fax: +44 (0)113 3432723; email: jrathbone{at}cochrane-sz.org
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODRESULTSDISCUSSIONREFERENCES |
|---|
Aims To evaluate Chinese herbal medicine as a treatmentfor schizophrenia.
Method A systematic review of randomised controlled trials (RCTs).
Results Seven trials were included. Most studies evaluated Chinese herbal medicine in combination with Western antipsychotic drugs; in these trials results tended to favour combination treatment compared with antipsychotic alone (Clinical Global Impression `not improved/worse' n=123, RR=0.19, 95% CI 0.1-0.6, NNT=6,95% CI 5-11; n=109, Brief Psychiatric Rating Scale `not improved/worse' RR=0.78,95% CI 0.5-1.2; n=109, Scale for the Assessment of Negative Symptoms `not improved/worse' RR=0.87,95% CI 0.7-1.2; n=109, Scale for the Assessment of Positive Symptoms `not improved/worse' RR=0.69,95% CI 0.5-1.0, NNT=6 95% CI 4-162). Medium-term study attrition was significantlyless for people allocated the herbal/antipsychotic mix (n=897, four RCTs, RR=0.34,95% CI 0.2-0.7, NNT=23,95% CI18-43).
Conclusions Results suggest that combining Chinese herbal medicine with antipsychotics is beneficial.
|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODRESULTSDISCUSSIONREFERENCES |
|---|
The methodology used in traditional Chinese medicine to diagnose and treat schizophrenia differs from that used in Western medicine. Traditional Chinese medicine differentiates cases of schizophrenia into syndromes, and it is these syndromes rather than the disease label such as schizophrenia or dian kuang (withdrawal mania), that determine treatment (Fig. 1). There are five main syndromes that fall within the disease category of dian kuang which may also include the Western diagnosis of schizophrenia. The five types are:
|
Each syndrome has a specific herbal formulation, but patients typically have mixed clinical presentations requiring formulas to be adapted by adding or subtracting herbs. To complicate matters, in China herbal medicines are sometimes used within the Western diagnostic paradigm alone without incorporating traditional theory. Nevertheless, because of the enormous population of China, even if herbal medicines are given to only a small proportion of the estimated 13 million Chinese people with schizophrenia, these treatment approaches could still be some of the most prevalent used for this illness.
|
|
METHOD |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODRESULTSDISCUSSIONREFERENCES |
|---|
Studies were identified from searches of the Cochrane Schizophrenia Group's register of trials, which incorporates regular searches of BIOSIS Inside, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO; the hand-searching of relevant journals and conference proceedings and searches of several grey literature sources. Additional databases searched included the Traditional Chinese Medical Literature Analysis and Retrieval System, the Chinese Biomedical Database, the China National Knowledge Infrastructure database and the Allied and Complementary Medicine Database (AMED). Full details of the English and Mandarin phrases used are reported elsewhere (Rathbone et al, 2005).
Data were not utilised from studies in which more than 50% of participants
in any group were lost to follow-up (this does not include the outcome of
`leaving the study early'). In studies with a less than 50% withdrawal rate
people leaving the study early were considered to have had the negative
outcome, except for the event of adverse effects and death. For binary
outcomes, the fixed-effects relative risk and its 95% confidence interval were
calculated. The numbers needed to treat/harm (NNT/NNH) were also calculated.
An estimate of the weighted mean difference (WMD) between groups and its 95%
confidence interval were calculated for continuous data. Data were not pooled
if standard deviations were too wide, suggesting considerable skew
(Altman & Bland, 1996).
Heterogeneity between studies was assessed by inspecting the relevant graph;
this was supplemented using the I2 statistic
(Higgins et al, 2003).
If inconsistency was high (
75%), the data were not pooled but were
presented separately and the reasons for heterogeneity investigated.
Citations were inspected independently by at least two reviewers. The reliability of the data extraction was checked using a 10% sample. Full reports of studies of agreed relevance were obtained, quality-rated (Alderson et al, 2004) and data extracted for details of methods, participants, interventions and outcomes. Disagreements between reviewers were discussed and if they could not be resolved further information was sought from authors. Main outcomes of interest were predefined as clinical response in global or mental state, adverse events including extrapyramidal adverse effects, service use including hospitalisation and relapse, quality of life, leaving the study early, death and economic evaluations.
|
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODRESULTSDISCUSSIONREFERENCES |
|---|
|
We identified 16 citations dating from 1987 to 2002 for the seven included studies. Overall, descriptions of studies were poorly reported. Two trials were available in both Chinese and English (Luo et al, 1997; Zhang et al, 2001), four in Chinese only (Meng et al, 1996; Zhu et al, 1996; Chen et al, 1997; Zhang et al, 1997) and one in English only (Zhang et al, 1987). All seven included studies were conducted in China and were described as being randomised, but none gave a description of the allocation procedure. Double-blind methodology was used in three studies, all of which used Ginkgo biloba extract (EGb761) combined with antipsychotics. All trials included in this review contained a moderate risk of bias (category B; Alderson et al, 2004). Trials ranged in sample size from 40 to 545 participants and lasted from 20 days to 6 months. Only one study (Zhang et al, 1997) attempted to allocate treatment according to traditional Chinese medicine syndrome differentiation. The other six studies employed Western diagnoses of schizophrenia with no further differentiation into the traditional Chinese syndromes, and six used operational diagnostic criteria. Three studies included people with chronic schizophrenia (mean duration 17 years), three did not report participants' history of illness and one study involved mostly people at first admission to hospital.
Herbal medicine alone v. chlorpromazine
Only one study (Zhang et al,
1987) gave the treatment group herbal medicines without the
addition of an antipsychotic. Over a 20-day period, global state outcome `not
improved/worse' significantly favoured the control group receiving
chlorpromazine (n=90; RR=1.88, 95% CI 1.2 to 2.9, NNH=4, 95% CI 2 to
14). No participant left the study early.
Herbal medicine plus antipsychotics v. antipsychotics alone
Herbal medicines given according to traditional Chinese medicine syndrome
differentiation – in only one study
(Zhang et al, 1997),
using dang gui cheng qi tang or xiao yao san – when
combined with antipsychotic medication (unspecified) scored significantly
lower for the outcome of global state `not improved/worse' than the control
group given unspecified antipsychotics (NNT=6, 95% CI 5 to 11;
Fig. 2(a)). Further global
state data from the Clinical Global Impression (CGI) scale – Meng et
al (1996), unknown
antipsychotic; Zhu et al
(1996), chlorpromazine –
also favoured the herbal medicine plus antipsychotic group
(Fig. 2(b)).
|
Adverse events are associated with antipsychotic medication, and combining herbal medicines with chlorpromazine (Zhu et al, 1996) did not mitigate extrapyramidal adverse effects, with both groups being equivocal. Constipation, however, was significantly lower in the herbal plus antipsychotic combination group (0/32) despite patients receiving the constipating antipsychotic chlorpromazine (n=67; RR=0.03, 95% CI 0.0 to 0.5; NNH=2, 95% CI 2 to 4); the comparison group (chlorpromazine alone) fared less well (19/35). Medium-term studies found significantly fewer patients leaving the study early (Fig. 2(e)) in the herbal plus antipsychotic group (n=897, four RCTs, RR=0.34, 95% CI 0.2 to 0.7; NNT=23, 95% CI 18 to 43).
Sensitivity analysis: Ginkgo biloba alone or plus antipsychotics v. antipsychotics
Studies of Ginkgo biloba were tested in a sensitivity analysis by
comparing them with the original pooled data (Ginkgo biloba data
pooled with other herbs). Effect sizes for CGI and BPRS scores were increased
for Ginkgo biloba when analysed separately, although these
differences were not statistically significant.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODRESULTSDISCUSSIONREFERENCES |
|---|
Herbal medicine alone v. antipsychotics
Global state measured as `not improved/worse' favoured the chlorpromazine
group (NNT with chlorpromazine 4, 95% CI 2 to 14) when compared with the
treatment group receiving dang gui cheng qi tang. This NNT concurs
with findings when chlorpromazine is compared with placebo
(Adams et al, 2007);
however, this is based on a single study (n=90;
Zhang et al, 1987)
lasting 20 days with participants given Chinese herbs according to a diagnosis
of schizophrenia without using traditional Chinese medicine differentiation.
Results must therefore be interpreted with caution given the design
limitations, but nevertheless do not support dang gui cheng qi tang
as a sole treatment for schizophrenia.
Herbal medicine plus antipsychotics v. antipsychotics alone
The herbal medicine group receiving either dang gui cheng qi tang
or xiao yao san plus antipsychotics were significantly less likely to
have an outcome of `no change or worse' compared with participants receiving
only antipsychotics, measured using the Clinical Global Impression scale
(NNT=6, 95% CI 5 to 11). This could be an important finding and does fit with
the CGI continuous scores. These results are broadly encouraging and suggest
that combining herbal medicines with antipsychotics might be beneficial,
although results are only based on two small studies (total n=103).
These vaguely positive finding also apply to mental state outcomes. The
dichotomised BPRS and SANS measures reported by Zhang et al
(2001); n=109) were
equivocal, but SAPS scores again showed borderline significance in favour of
the herbal medicine plus antipsychotic combination. Medium-term continuous
SANS data, however, provided more robust results, with three studies
(n=741) favouring the herbal plus antipsychotic combination group.
The experimental group had, on average, nine points less on this scale than
those allocated to antipsychotic drugs alone. In our opinion, in this group of
chronically unwell people such an average difference would be noticeable and
clinically meaningful. Further supporting this improvement, both short-term
and medium-term BPRS scores were significantly better for those receiving
herbal medicines plus antipsychotics compared with those receiving
antipsychotic drugs alone, although there was heterogeneity in these results.
The latter might have been due to the use of different antipsychotic drugs
between trials.
Adverse effect Treatment Emergent Signs and Symptoms scores were reported by Zhang et al (2001), but standard deviations were wide and no conclusion can be made with confidence. Only one study (Zhu et al, 1996; n=67) reported extrapyramidal symptoms, and these were not significantly different between groups. In one trial in which both groups were given chlorpromazine, constipation was significantly more frequent in the control group (NNH=2). In this trial the herb used was a purgative used also in Western medicine – Rhizoma rhei palmatum (rhubarb).
Numbers of participants leaving the study early in the short term were similar for both groups. Medium-term data showed significantly fewer left early in the herbal medicine plus antipsychotic group compared with people receiving only antipsychotics (n=897; 2% v. 7%). In the context of these studies, the addition of herbal medicine did not worsen treatment compliance and there is the suggestion that the addition of the herbal medicine made it easier for participants to take standard antipsychotics.
We did a post hoc sensitivity analysis for the single herb Ginkgo biloba, used outside the traditional Chinese medicine approach within a Western model of schizophrenia. We found no evidence that this particular herb had remarkable effects.
The application of traditional Chinese herbal medicine is fundamentally interwoven with syndrome differentiation. Failure to apply syndrome differentiation may result in treatments being ineffective or even harmful. Despite this, there is some evidence that these Chinese herbal medicines, combined with antipsychotics and given in a way that is not in keeping with their normal use within traditional Chinese medicine, may be beneficial for people with schizophrenia across a range of outcomes. If these medicines are used within their usual context the positive effects could be greater. Even the gains seen in this review would still be important for the millions for whom these treatments are used. Both West and East need well-reported (Moher et al, 2001) randomised trials that are adequately powered, blinded and of sufficient duration so we can detect meaningful treatment effects with high levels of confidence.
|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODRESULTSDISCUSSIONREFERENCES |
|---|
Alderson, P., Green, S. & Higgins, J. P. T. (2004) Cochrane Reviewers' Handbook 4.2.2. Cochrane Library, issue 1. Wiley.
Altman, D. G. & Bland, J. M. (1996)
Detecting skewness from summary information. BMJ,
313, 1200.
Brenner, H. D., Dencker, S. J., Goldstein, M. J., et al
(1990) Defining treatment refractoriness in schizophrenia.
Schizophrenia Bulletin,
16, 551
-561.
Cao, X. D. & Wang, W. (2000) Comparison between therapeutic effect of risperidone in treating different traditional Chinese medicine syndrome types of first-episode schizophrenia. Chinese Journal of Integrated Traditional and Western Medicine, 20, 421 -423.
Chen, Y. D., He, A. N. & Chen, L. (1997) The clinical observation on 120 cases of schizophrenic negative symptoms treated with `Xin Shen' mixture. Journal of University Traditional Chinese Medicine, 22, 19 -21.
Gong, M. F., Zu, Y. M., Jin, P., et al (2000) Clinical investigation of Qingnao Anshen decoction on hemorrheology in the patients with schizophrenia and depression. Hebei Journal of Traditional Chinese Medicine, 22, 571 -573.
Han, B., Zhang, M., Liu, L., et al (2002) Adouble blind controlled trial of traditional Chinese medicine and clozapine in schizophrenia (abstract). International Journal of Neuropsychopharmacology, 5 (suppl. 1), 190 .
Higgins, J. P., Thompson, S. G., Deeks, J. J., et al
(2003) Measuring inconsistency in meta-analyses.
BMJ, 327, 557
-560.
Luo, H. C., Shen, Y. & Meng, F. Q. (1997) Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia - a double blind study. Chung-Kuo Chung Hsi I Chieh Ho Tsa Chih, 17, 139 -142.
Meng, F. Q., Cui, Y. H. & Wang, S. H. (1996) Adouble-blind placebo controlled study of EGb761 in the treatment of chronic schizophrenia. Journal of Clinical Psychological Medicine, 6, 339 -341.
Ming, Z. (2001) The Medical Classic of the Yellow Emperor. Foreign Language Press.
Moher, D., Schulz, K. F. & Altman, D.
(2001) The CONSORT statement: revised recommendations for
improving the quality of reports of parallel-group randomized trials.
JAMA, 285, 1987
-1991.
Rathbone, J., Zhang, L., Zhang, M., et al (2005) Chinese herbal medicine for schizophrenia. Cochrane Database of Systematic Reviews, issue 4. Wiley.
Rong, Y. (2001) Controlled treatment of Que-Dian decoctionwithlowdosage decoction with low dosage of ofclozapineintreating clozapine in treating schizophrenia. Zhe Jiang Zhong Xi Yi Jie He Za Zhi, 11, 470 -471.
Saku, M. (1991) The current clinical practice of herbal medicine in psychiatry in mainland China: a review of literature. Japanese Journal of Psychiatry and Neurology, 45, 825 -832.
Wang, B. (1998a) Traditional Chinese medical treatment to invigorate blood and relieve stasis treatment of schizophrenia: comparison with antipsychotic treatment. Psychiatry and Clinical Neuroscience, 52, 329 -330.
Wang, B. (1998b) A controlled study of the efficacy of Chinese herb medicine in schizophrenic patients. Chinese Journal of Neurology and Psychiatry, 18, 44-46.
Zhang, J. (1996) Current status of integrated traditional and Western medicine study on schizophrenia. Chinese Journal of Integrated Traditional and Western medicine, 16, 643 -645.
Zhang, L. D., Tang, Y. H., Zhu, W. B., et al (1987) Comparative study of schizophrenia treatment with electroacupuncture, herbs and chlorpromazine. Chinese Medical Journal, 100, 152 -157. 152-157.[Medline]
Zhang, L. D., Zhou, G. & Jin, Z. Y. (1997) Biochemical study on TCM treatment of schizophrenia based on syndrome typing. Journal of Traditional Chinese Medicine, 38, 173 -175.
Zhang, Y. Z., Zhou, D. F., Zhang, P. Y., et al (2001) A double-blind, placebo placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry, 62, 878 -883.
Zhao, X. Y., He, M. & Luo, H. (1997) Effects of Ginkgo biloba special extract Egb761 on nailfold microcirculation and symptoms of chronic schizophrenics. Chinese Journal of Microcirculation, 7, 25 -27.
Zhen, H. B. & Feng, R. S. (1992) Chinese drug therapy in treatment of schizophrenia. Chinese Journal of Nervous and Mental Disorders, 18, 362 -363.
Zhu, Y. Z., Kang, B. & Zhu, Q. Q. (1996) Clinical study of shuizhi-dahuang mixture in treating schizophrenics with blood stasis syndrome. Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih, 16, 646 -648.
Received for publication May 31, 2006. Revision received September 8, 2006. Accepted for publication January 16, 2007.
Related articles in BJP:
This article has been cited by other articles:
|
|
 |
|
  P. Tyrer From the Editor's desk The British Journal of Psychiatry, July 1, 2008; 193(1): 90 - 90. [Full Text] [PDF]
|
|
|
|
|
|
P. Tyrer A journal describing present undertakings, studies and labours of the ingenious The British Journal of Psychiatry, January 1, 2008; 192(1): 1 - 2. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
